MedPath

Microsurgical management Of Gingival Recession Defects With Autologous Platelet Rich Fibrin (PRF) And Autogenous Connective Tissue Graft (CTG) In Conjunction With Coronally Advanced Flap: A Comparative Clinical Study

Completed
Conditions
Dental patients having Class I and Class II gingival resession in uppr anterior teeth
Registration Number
CTRI/2017/10/010136
Lead Sponsor
Saraswati Dental College Lucknow
Brief Summary

**Purpose:** To evaluate autologous Platelet Rich Fibrin (PRF) and autogenous Connective Tissue Graft (CTG) in gingival recession defects in conjunction with coronally advanced flap (CAF) using microsurgical technique.

**Materials and Methods:** Forty-five class I and II recession defects were randomly equally (n=15) divided into three groups: Group I sites treated with CAF with PRF; Group II sites treated with CAF with CTG and Group III sites treated with CAF alone using microsurgical approach in 36 patients.  Parameters recorded were vertical (VGR) and horizontal gingival recession (HGR), % Complete root coverage (CRC), Patient comfort score (PCS), Patient esthetic score (PES) and Hypersensitivity score (HS) at 10 days, 3 months and 6 months.

**Results:** CAF surgery alone and in combination with PRF or CTG, are effective  procedures to cover denuded roots with mean VGR values of 1.26±0.70 mm (74.4%),  1.26±0.59 mm (58%) and 1.06±0.79 mm (53.3%) for Group I, II and III. In terms of complete root coverage (CRC) achieved at 6 months, results showed that 100% CRC was obtained in 60 % sites of Group I, 20 % sites of Group II and 27% in Group III. Patient response and acceptance for surgical treatment modality in terms of PCS and PES was highest for Group I (PRF and CAF) followed by Group III, and Group II; and there was decrease in hypersensitivity score (HS) for Group I (PRF and CAF) while no significant changes in HS scores were observed for Group II and Group III.At the end of six months follow-up there was significant increase in gingival thickness measurements using transgingival probing in Group II, whereas non-significant changes were observed in Group 1and Group III.

**Conclusions:** Long term multicentric randomized controlled clinical study may be necessary to evaluate the clinical outcome for autologous PRF in comparison to CTG and CAF alone.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
36
Inclusion Criteria

Patients (1) having at least one tooth in maxillary anterior teeth region with Millers Class I or Class II labial gingival recession defect; (2) in good general health (ASA-I) with no contraindications for periodontal surgery; (3) not using antibiotics, corticosteroids, chemotherapeutics, immunomodulators, or others that modify the results of periodontal therapy during the last six months; (4) selected teeth must be free of endodontic treatment, buccal or interproximal restoration; (5) who have not undergone any periodontal treatment in the preceding six months of initial examination.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hypersensitivity score,At 3 months and 6 months post-intervention
Probing pocket depth,At 3 months and 6 months post-intervention
Clinical attachment level,At 3 months and 6 months post-intervention
Horizontal gingival recession,At 3 months and 6 months post-intervention
at 3 months and 6 monthsAt 3 months and 6 months post-intervention
Vertical gingival recession,At 3 months and 6 months post-intervention
Patient esthetic score,At 3 months and 6 months post-intervention
Patient comfort score,At 3 months and 6 months post-intervention
Secondary Outcome Measures
NameTimeMethod
Gingival thicknessPatient esthetic score,

Trial Locations

Locations (1)

Sraswati Dental College, Lucknow

🇮🇳

Lucknow, UTTAR PRADESH, India

Sraswati Dental College, Lucknow
🇮🇳Lucknow, UTTAR PRADESH, India
Dr Vivek Kmuar Bains
Principal investigator
9935023439
doc_vivek76@yahoo.co.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.